Alerta

PARTIAL PEPTIDE OF SARS-COV-2 SPIKE PROTEIN FOR INDUCING FOLLICULAR HELPER T CELLS

Resumen de: EP4692109A1

It aims to provide a composition for inducing follicular helper T cell reactive to SARS-CoV-2. A partial peptide of the spike protein of SARS-CoV-2 is provided, which contains an amino acid sequence selected from the group consisting of the following (1) to (17) and has a full length of 15 or less amino acids:(1) FKIYSKHTPIN (SEQ ID NO: 1),(2) FQFCNDPFLGVYYHK (SEQ ID NO: 2),(3) KRFDNPVLPFN (SEQ ID NO: 3),(4) LLQYGSFCTQL (SEQ ID NO: 4),(5) PPAYTNSFTRGVYYP (SEQ ID NO: 5),(6) CSNLLLQYGSFCTQL (SEQ ID NO: 6),(7) SKRSFIEDLLFNKVT (SEQ ID NO: 7),(8) TGVLTESNKKFLPFQ (SEQ ID NO: 8),(9) TNGTKRFDNPVLPFN (SEQ ID NO: 9),(10) NQFNSAIGKIQ (SEQ ID NO: 10),(11) NFTISVTTEIL (SEQ ID NO: 11),(12) STEIYQAGSTPCNGV (SEQ ID NO: 12),(13) KVFRSSVLHST (SEQ ID NO: 13),(14) EIRASANLAAT (SEQ ID NO: 14),(15) NFTISVTTEILPVSM (SEQ ID NO: 15),(16) FIKQYGDCLGDIAAR (SEQ ID NO: 16), and(17) FIEDLLFNKVTLADA (SEQ ID NO: 17).

HUMAN ANTIBODY AGAINST CORONAVIRUS MUTANT STRAIN, OR ANTIGEN-BINDING FRAGMENT THEREOF

Resumen de: WO2026029035A1

The purpose of the present invention is to provide an antibody against a coronavirus (SARS-CoV-2) mutant strain, in particular, an omicron substrain. Moreover, another purpose of the present invention is to provide a pharmaceutical composition against coronavirus infections, the pharmaceutical composition using said antibody. The present invention provides: an antibody that binds to a spike protein of coronavirus and has the ability to neutralize coronavirus including an omicron substrain, or an antigen-binding fragment thereof; and a pharmaceutical composition for preventing or treating coronavirus infections, the pharmaceutical composition comprising said antibody or antigen-binding fragment thereof.

COMPOSITIONS CONTAINING VERTEPORFIN, RIBAVIRIN, GEMCITABINE, OR COMBINATIONS THEREOF AND METHODS OF USE FOR TREATING COVID-19, CANCER, OR NON CANCER DISEASES

Resumen de: US20260034097A1

Disclosed are pharmaceutical formulations and methods using Verteporfin, Ribavirin, and/or Gemcitabine for use in the treatment of diseases by various routes of administration including inhalation, intratumoral, topical and/or systemic injection administration. This invention relates more specifically to the use of Verteporfin, Ribavirin, Gemcitabine, and/or combinations thereof as an inhaled dry powder treatment for COVID-19 and/or other lung infections, cancer and other non-cancer applications, which may be followed by other treatment regimens including radiation therapy, photodynamic therapy, and/or sonodynamic therapy. These pharmaceutical compositions containing one or more of Verteporfin, Ribavirin, and Gemcitabine may be included in pharmaceutical kits containing the compositions, and to methods for the treatment of cancer and non-cancer diseases with the active agents of the pharmaceutical compositions. The administering of Verteporfin alone or in combination with Ribavirin and Gemcitabine may be followed or co-administered with photodynamic and/or sonodynamic therapy (PDT/SDT).

VIRUS-LIKE VESICLES (VLVS) BASED VACCINES AND METHODS OF PREVENTING, AMELIORATING, AND/OR TREATING COVID-19 AND/OR HEPATOCELLULAR CARCINOMA (HCC)

Resumen de: US20260034208A1

The present disclosure relates to the discovery of compositions and methods for therapeutic immunization for SARS-CoV-2 infections and/or disease(s) associated with expression of Glypican-3 (GPC3), including but not limited to cancers such as hepatocellular carcinoma (HCC). Methods of the disclosure include a method of generating virus like vesicles (VLVs), VLVs comprising SARS-CoV-2 antigens from a high titer VLV producing vector, VLVs comprising GPC3 antigens from a high titer VLV producing vector, methods of treating, ameliorating, and/or preventing SARS-COV-2 infection, methods of inducing a memory T and B cell immune response against SARS-CoV-2 infection in a, methods of treating, ameliorating, and/or preventing GPC3 associated disease, and methods of inducing a memory T and B cell immune response against GPC3 in a subject. Furthermore, the disclosure encompasses a pharmaceutical composition for vaccinating a subject to protect the subject against infection with

HUMAN BROADLY NEUTRALIZING ANTIBODIES AGAINST BETACORONAVIRUSES

Resumen de: US20260035438A1

The invention provides novel broadly neutralizing antibodies and related antibody compositions against betacoronaviruses, e.g., SARS-CoV-2. Also provided in the invention are polynucleotides and vectors encoding such antibodies, as well as pharmaceutical compositions containing the antibodies or polynucleotides. Therapeutic uses of the antibodies or pharmaceutical compositions in preventing or treating betacoronaviral infections (e.g., SARS-CoV-2 infection) are also encompassed by the invention.

Anti-Sars-COV-2 Antibodies and Uses Thereof

Resumen de: US20260035439A1

Provided herein are monoclonal antibodies that specifically bind to an anti-SARS-CoV-2 spike(S) protein, and methods of using said antibodies.

CORONAVIRUS VACCINE, PRODUCTION AND APPLICATION

Resumen de: US20260034209A1

An SARS-COV-2 recombinant Spike protein is provided. The research process of the protein is as follows: the dominant strain in circulation was identified by screening clinical samples of SARS-COV-2 patients and its mutations in Turkey were evaluated by sequencing the Spike gene. Sequencing data and in silico methods were used to design the Spike antigen and then the novel Spike antigen was docked with the human ACE2 (Angiotensin Converting Enzyme-2) receptor to determine the binding energy. After DNA vaccine construction, HEK293T cells were transfected and analyzed for protein expression capacity by IFA, Western blot and RT-qPCR, then BALB/c mice and K18-hACE2 transgenic mice were immunized with DNA vaccine administered intramuscularly (IM) and intradermally (ID) using an electroporator device three times on days 0, 14 and 56. Humoral and cellular immune responses were then analyzed using recombinant ELISA, Western blot, surrogate virus neutralization assay, microneutralization assay, Cytokine ELISA and flow cytometry.

HUMAN ANTI-SARS-COV-2 SPIKE (S) ANTIBODIES

Resumen de: WO2026030604A1

The present invention includes a monoclonal antibody or antigen-binding fragment thereof, methods of using, detection, recombinant vectors, host cells, kits, variants, and pharmaceutical compositions that include the antibody or antigen-binding fragment thereof that binds to the SARS-CoV-2 Spike protein.

SARS-COV-2 RNA VACCINES AND USES THEREOF

Resumen de: AU2024308310A1

The present disclosure relates to SARS-CoV-2 RNA vaccines and uses thereof. The present disclosure also relates to conventional mRNA vaccines and self-replicating RNA vaccines for the treatment of a SARS-CoV-2 infection or COVID-19.

SARS-COV-2 VACCINE

Resumen de: WO2026030724A1

Provided herein are recombinant SARS-CoV-2 Spike proteins and fragments thereof comprising the receptor binding domain (RBD), which have utility, for example, for elicitation of an immune response to SARS-CoV-2 in a subject. Also provided are nucleic acid molecules and vectors encoding these proteins, as well as methods of their use and production. In several implementations, the disclosed recombinant SARS-CoV-2 Spike proteins and fragments thereof comprising the RBD, can be used to generate an immune response to SARS-CoV-2 in a subject, for example to treat or prevent or reduce the severity of SARS-CoV-2 infection.

MACROCYCLIC PEPTIDOMIMETICS AS ANTIVIRAL AGENTS

Resumen de: EP4686470A1

The present invention refers to macrocyclic peptides as covalent reversible inhibitors of SARS-CoV-2 M^pro with a potential broad-spectrum activity against CoV proteases. The compounds are therefore indicated for treating M^pro associated or mediated diseases and conditions, such as severe acute respiratory syndrome coronavirus 2 (SARS-CoV2).

-2 MULTI-EPITOPE BASED SARS-COV-2 VACCINE COMPOSITION

Resumen de: WO2026023869A1

The present application relates to a vaccine composition comprising peptides isolated from structural proteins of SARS-CoV-2.

-2 METHOD FOR EXTRACTING EPITOPES EFFECTIVE IN PREVENTING OR TREATING SARS-COV-2

Resumen de: WO2026023870A1

The present application relates to a method for extracting epitopes effective in the prevention or treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the method comprising the steps of: (a) extracting, from an anti-spike antibody database, first structural data including known structures and second structural data including unknown structures, and extracting, from a SARS-CoV-2 proteome database, third structural data including known structures; (b) carrying out 3D modeling on the second structural data, and classifying the third structural data into a first group including structural proteins and a second group including both structural proteins and non-structural proteins; (c) carrying out spike-antibody docking on the basis of the first group and the second structural data on which 3D modeling has been carried out; (d) constructing a spike-antibody database on the basis of the first structural data and the docked data, and predicting conformational epitopes on the basis of the second group; (e) characterizing epitopes on the basis of the spike-antibody database and the conformational epitopes; and (f) selecting final epitopes on the basis of analysis results.

VIRUS-LIKE PARTICLES FOR THE TREATMENT OF SARS-COV2

Resumen de: MX2025014589A

The present disclosure relates to a virus-like particle (VLP) comprising one or more antigens for use as a vaccine. The present disclosure further relates to uses of the vaccine for the treatment of a SARS-CoV-2 infection or coronavirus disease 2019 (COVID-19).

CORONAVIRUS AND INFLUENZA COMPOSITIONS AND METHODS FOR USING THEM

Resumen de: MX2025011740A

An immunogenic composition for inducing immune responses against both influenza and coronaviruses includes: (a) a coronavirus S (CoV S) glycoprotein in the form of a detergent-core nanoparticle, wherein the detergent is a non-ionic detergent; (b) at least three hemagglutinin (HA) glycoproteins, wherein each HA glycoprotein is from a different influenza strain; and (c) a pharmaceutically acceptable buffer. An immunogenic composition for inducing immune response against influenza includes: (a) at least three hemagglutinin (HA) glycoproteins, wherein each HA glycoprotein is from a different influenza strain, wherein from 30 to 60 µg of HA per strain is present in the composition; and (b) a pharmaceutically acceptable buffer. The immunogenic compositions may include an adjuvant. Methods of stimulating an immune response against SARS-CoV-2, a heterogeneous SARS-CoV-2 strain, an influenza virus, or a combination thereof include the administration of the immunogenic compositions.

ANTIGENO RECOMBINANTE DE LA PROTEINA SPIKE DEL SARS-COV -2.

Resumen de: MX2024009232A

The present application is in the field of genetic engineering, biotechnological and in particular in the design and production of synthetic genes in different strains of Escherichia coli resulting in soluble molecules with antigenic capacity against the SARS-CoV2 virus. This method is summarized in three phases which are: The application of molecular engineering for obtaining the DNA sequence that allows E coli to produce SARS-CoV2 viral antigens, followed by integration of the designed vector into E coli cells to obtain recombinant strains and finally the production and purification of recombinant viral antigens of SARS-CoV2 in E coli.

Vaccines against coronavirus and methods of use

Resumen de: NZ791834A

Disclosed herein are nucleic acid molecules encoding a Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2) spike antigen, SARS-CoV-2 spike antigens, immunogenic compositions, and vaccines and their use in inducing immune responses and protecting against or treating a SARS-CoV-2 infection in a subject.

METHOD AND DEVICE FOR ACTIVATION OF ACUPOINTS USING A TESLA COIL BY MEANS OF APPLYING A GROUND CONNECTION

Resumen de: RS20240787A1

Method and device for applying an electrical stimulus to an acupuncture point using an electrode connected to ground on a patient exposed to the emitted electromagnetic field of a Tesla transformer. The intention of the invention is increasing the effectiveness of acupuncture treatment, while making its use painless for the general population, and especially suitable for the pediatric population. The device can be used to relieve symptoms and pain caused by trauma, post-Covid 19 syndrome, for prevention of worsening of such symptoms, for the prevention and treatment of symptoms associated with depression and other psychiatric, neurological and developmental disorders, including major depressive disorder, Alzheimer's disease and autism. The device consists of a Tesla transformer (1) and an electrode or set of electrodes (6) connected to an electrical ground (4). The Tesla transformer (1) consists of a primary coil (1.a), a secondary coil (1.b), a feedback coil (1.c) and a control circuit (2). The system also includes a variable resistor (7), which regulates the radiation intensity of the Tesla transformer (1).

A KIT AND AN ASSAY FOR ANALYSING THE PRESENCE OF NEUTRALIZING ANTIBODY AGAINST SARS-COV-2

Resumen de: AU2024335376A1

The present disclosure relates to in vitro identification of neutralizing antibody against Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2). Specifically, the present disclosure relates a kit and an in vitro assay for analyzing the presence of neutralizing antibody/inhibitors which could block or inactivate receptor binding domain of the spike protein of SARS-CoV-2.

PSEUDOVIRUS BASED NEUTRALIZATION ASSAY FOR EVALUATING VACCINE IMMUNOGENICITY

Resumen de: US20260028644A1

Provided herein are pseudoviruses expressing a SARS-CoV-2 S glycoprotein. Also provided herein are assays that employ the pseudoviruses to evaluate the immunogenicity of a biological sample against a SARS-CoV-2 virus or variant thereof. Also provided herein are methods of evaluating the immunogenicity of a COVID-19 vaccine using the assays.

Saliva Stabilization Solution For Use In Nucleic Acid Amplification Reactions And Methods Of Use For The Detection Of Pathogen Nucleic Acids

Resumen de: US20260028685A1

In one aspect, the inventive technology relates to improved systems, methods, and compositions for a novel saliva stabilization solution for use in nucleic acid amplification reactions, and in particular embodiment its use in the detection of pathogen nucleic acids, such as SARS-CoV-2 (COVID-19).

PREFERENTIAL DEPLETION OF TCF1+ PROGENITOR T-CELLS IN SEVERE COVID-19 AS MEDIATED BY INTERLEUKIN 12 (IL-12)

Resumen de: US20260028673A1

The coronavirus disease 2019 (COVID-19) pandemic caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues to be a threat to global public health. While some individuals exhibit mild symptoms, others develop severe disease leading to severe lymphopenia and death. Provided herein are methods for determining whether a subject suffering from a SARS-Cov-2 infection is more likely to suffer from severe or mild disease. Also provided are methods for predicting whether a subject suffering from a SARS-Cov-2 infection with mild disease will progress to more severe disease and methods for treating patients having an infection via SARS-Cov-2 and related family members.

METHOD FOR PRETREATMENT OF SPECIMEN FOR IMMUNOCHROMATOGRAPHIC TEST

Resumen de: US20260029316A1

An immunochromatographic method for a trace amount of an antigen or an antibody such as SARS-COV-2 including use of saliva, enabling highly sensitive immunochromatographic antigen or antibody detection even when the saliva is used. A method for pretreatment of a specimen for an immunochromatographic test, including passing the saliva through a porous member capable of supporting a viscous component in the saliva to remove the viscous component, passing the liquid that has passed through the porous member through a filter having a hole diameter of from 0.1 μm to 10 μm, and concentrating an antigen or an antibody in the liquid that has passed through the filter.

POLYPEPTIDE CAPABLE OF INHIBITING MERS-LIKE CORONAVIRUS INFECTION, AND USE THEREOF

Resumen de: WO2026021236A1

Provided are a polypeptide capable of inhibiting a MERS-like coronavirus infection, and a use thereof. On the basis of a membrane fusion invasion feature mediated by an S2 subunit of a MjHKU4r-CoV coronavirus S protein, a group of polypeptides are invented by using the HR1 functional domain of the protein as a target. The polypeptides can efficiently inhibit the membrane fusion invasion process of a MERS-like coronavirus MjHKU4r-CoV. By competitively binding to a viral HR1 functional domain, these polypeptides inhibit the formation of a viral 6-helix bundle (6-HB) fusion core, thereby efficiently blocking the process of the coronavirus MjHKU4r-CoV invading a target cell. The present invention can provide an efficient preventive and therapeutic candidate drug for prevention and treatment of the MERS-like coronavirus MjHKU4r-CoV having potential high pathogenicity and cross-species transmission.

MULTIPLE EPITOPE-BASED SARS-COV-2 VACCINE COMPOSITION

Nº publicación: WO2026023869A1 29/01/2026

Solicitante:

AJOU UNIV INDUSTRY ACADEMIC COOPERATION FOUNDATION [KR]
\uC544\uC8FC\uB300\uD559\uAD50 \uC0B0\uD559\uD611\uB825\uB2E8

Resumen de: WO2026023869A1

The present application relates to a vaccine composition comprising peptides isolated from structural proteins of SARS-CoV-2.